<DOC>
	<DOCNO>NCT02678598</DOCNO>
	<brief_summary>The objective study evaluate efficacy intravenous micafungin empirical antifungal therapy , pre-emptive antifungal therapy , diagnostic driven antifungal therapy target antifungal therapy patient invasive fungal infection cause Candida sp . Aspergillus sp . ( fungemia , respiratory mycosis , gastrointestinal mycosis ) adult patient China .</brief_summary>
	<brief_title>A Retrospective Study Evaluating Efficacy Safety Micafungin Sodium Treatment Invasive Fungal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients receive Micafungin empirical antifungal therapy , preemptive antifungal therapy , diagnostic driven antifungal therapy target antifungal therapy Patients receive Micafungin treatment least 1 dose Patients receive Micafungin treatment combine antifungal drug time Neither efficacy safety evaluate miss data , confuse record</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Candida</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Antifungal</keyword>
</DOC>